Actelion's Phase II selexipag data impresses analysts
This article was originally published in Scrip
Executive Summary
Actelion's selexipag (formerly known as ACT-293987) was safe and effective in a Phase IIa trial in pulmonary arterial hypertension, show data presented at the American Thoracic Society (ATS) meeting. The Phase III GRIPHON trial of the orally available prostanoid is currently ongoing, with results due mid 2013.